Antihypertensive Drugs Therapy in Hypertension and Covid-19 Comorbidity

Emuesiri Goodies Moke (Delta State University, Abraka)
Endurance Efe Ahama (Delta State University, Abraka)
Pere-Ebi Yabrade Toloyai (Delta State University, Abraka)
Mamerhi Taniyohwo Enaohwo (Delta State University, Abraka)
Ekuerhare Basil (Delta State University, Abraka)
Emuesiri Kohworho Umukoro (Delta State University, Abraka)
Anthony Taghogho Eduviere (Delta State University, Abraka)
Ikuesirioghene Udumebraye (Delta State University, Abraka)
Choice Udufowe (Delta State University, Abraka)

Biology, Medicine, & Natural Product Chemistry
Vol 12, No 1 (2023)

The novel coronavirus (CoV) severe acute respiratory syndrome (SARS)-CoV-2 outbreak began at the end of 2019 in Wuhan, China, and has spread to over 200 countries. Many comorbidities have shown to be associated with the severity of the viral infection with hypertension being one of the highest rated comorbidities since loss of the ACE2 receptor due to SARS-Cov-2 infection can lead to increased blood pressure. The effects and clinical characteristics associated with the use of beta-blockers, angiotensin receptor blockers (ARB), and calcium-channel blockers (CCB) shows not to affect the outcome of covid-19, except in angiotensin converting enzyme inhibitor (ACEI) which may have negative outcomes on covid-19 infected patients. Many comorbidities have shown to be associated with the severity of the viral infection.